Extract
We read with interest the articles by Sotgiu et al. [1] and Dalcolmo et al. [2], which initiated a debate on the suitability of the shorter regimen for multidrug-resistant (MDR) tuberculosis (TB) cases in different settings [2–6]. The shorter World Health Organization (WHO) regimen [7, 8] is composed of an initial phase of 4–6 months of kanamycin, moxifloxacin, prothionamide, clofazimine, pyrazinamide, high-dose isoniazid and ethambutol, followed by 5 months of moxifloxacin, clofazimine, pyrazinamide and ethambutol.
Abstract
Comparing phenotypic and genotypic results in Mexico: guidance for the adoption of the shorter MDR-TB regimen http://ow.ly/MOxJ30hXkjd
Footnotes
Conflict of interest: None declared.
- Received November 2, 2017.
- Accepted December 27, 2017.
- Copyright ©ERS 2018